drugset
Drugs / VBI-S
last change Sep 2024 re-read 3 minutes ago

VBI-S

Other / unclassified

Developed for
infectious disease with sepsis
Investigated by
Vivacelle Bio

Trials 1

today NCT04257136 · Ph 2
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04257136 Feb 2020 → Dec 2023 infectious disease with sepsis Vivacelle Bio Unknown Met primary

Press releases naming this drug 8 releases

DateIssuerRelease
2024-09-03 Vivacelle Bio Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S vivacellebio.com ↗
2024-07-23 Vivacelle Bio Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock vivacellebio.com ↗
2024-02-29 Vivacelle Bio Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients vivacellebio.com ↗
2024-01-04 Vivacelle Bio The Lancet Journal – Efficacy and Safety of Phospholipid Nanoparticles (VBI-S) in Reversing Intractable Hypotension in Patients with Septic Shock vivacellebio.com ↗
2023-10-10 Vivacelle Bio VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients vivacellebio.com ↗
2023-02-10 Vivacelle Bio Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients vivacellebio.com ↗
2022-10-20 Vivacelle Bio (BPRW) Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis vivacellebio.com ↗
2020-11-24 Vivacelle Bio Vivacelle Bio Receives $5.3 Million Award from the US Navy for a Clinical Trial of VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens vivacellebio.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as VBI-S ClinicalTrials.gov intervention name — accepted as the source's own label NCT04257136 ↗
Modality Other / unclassified “hydrophobic phospholipid nanoparticles (VBI-S)” PMID 38545092 ↗ Jan 2024
Route Intravenous “VBI-S was administered intravenously” PMID 38545092 ↗ Jan 2024